Regulus Therapeutics Inc. (RGLS)
NASDAQ: RGLS
· Real-Time Price · USD
8.16
0.00 (0.00%)
At close: Jun 24, 2025, 3:59 PM
Regulus Therapeutics Cash Flow Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Net Income | -9.63M | -12.79M | -14.06M | -11.04M | -8.47M | -8.06M | -7.82M | -7.01M | -7.14M | -6.79M | -7.55M | -7.26M | -6.72M | -7.13M | -8.63M | -6.03M | -6.01M |
Depreciation & Amortization | -115K | 87K | -1.08M | 89K | 81K | 76K | 56K | 47K | 48K | 33K | 32K | 31K | 26K | 41K | 38K | 45K | 335K |
Stock-Based Compensation | 2.25M | 2.46M | 2.42M | 1.86M | 985K | 1.04M | 973K | 382K | 410K | 397K | 360K | 420K | 1M | 671K | 807K | 754K | 691K |
Other Working Capital | n/a | -1.37M | 3.17M | -2.05M | -1.7M | 1.24M | 301K | 500K | -1.81M | 834K | 227K | 665K | -1.07M | -1.12M | 3.01M | 278K | -1.01M |
Other Non-Cash Items | n/a | -385K | -84K | 1.15M | 1.11M | 1.56M | 32K | 50K | -25K | -101K | -1K | 12K | 38K | 7K | 17K | 12K | 10K |
Deferred Income Tax | n/a | n/a | n/a | n/a | n/a | -1.58M | -51K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | -662K | n/a |
Change in Working Capital | n/a | -1.22M | 3.36M | -1.86M | -1.5M | 846K | 537K | 282K | -1.41M | 213K | 427K | 636K | -726K | -1.42M | 2.2M | 861K | -734K |
Operating Cash Flow | -10.61M | -11.85M | -9.45M | -11.64M | -8.74M | -6.13M | -6.28M | -6.25M | -8.11M | -6.25M | -6.73M | -6.16M | -6.38M | -7.83M | -5.56M | -5.02M | -5.71M |
Capital Expenditures | 268K | n/a | -28K | -83K | -229K | -71K | -541K | n/a | -1K | -63K | -3K | -193K | -102K | -41K | -26K | -131K | -53K |
Cash Acquisitions | n/a | n/a | n/a | n/a | n/a | 3K | n/a | n/a | n/a | 5M | -5M | n/a | n/a | n/a | n/a | n/a | n/a |
Purchase of Investments | n/a | n/a | -5.33M | n/a | -78.31M | -5K | -4.9M | n/a | n/a | -2.47M | -17.86M | -12.43M | n/a | n/a | n/a | n/a | n/a |
Sales Maturities Of Investments | 21.5M | 24M | 24M | n/a | n/a | 5M | n/a | n/a | 15M | 13M | 5M | n/a | n/a | n/a | n/a | n/a | n/a |
Other Investing Acitivies | -268K | n/a | n/a | n/a | -78.31M | 5K | -4.9K | n/a | 15K | -5M | 5M | -12.43K | n/a | n/a | n/a | n/a | n/a |
Investing Cash Flow | 21.5M | 24M | 18.64M | -83K | -78.54M | 4.93M | -5.44M | n/a | 15M | 10.47M | -12.86M | -12.62M | -102K | -41K | -26K | -131K | -53K |
Debt Repayment | n/a | n/a | n/a | -551K | -826K | -826K | -826K | -826K | -826K | n/a | n/a | n/a | n/a | 1K | -9K | n/a | -72K |
Common Stock Repurchased | n/a | n/a | 74K | -74K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Dividend Paid | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Other Financial Acitivies | n/a | n/a | n/a | n/a | 2K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 1K | 26K |
Financial Cash Flow | 45K | n/a | 56K | -744K | 93.11M | -873K | 287K | 13.21M | -805K | 2K | 4.49M | 2K | 2K | 32.41M | -4K | 15M | 6.34M |
Net Cash Flow | 10.93M | 12.15M | 9.25M | -12.46M | 5.82M | -2.07M | -11.43M | 6.96M | 6.08M | 4.21M | -15.11M | -18.78M | -6.48M | 24.54M | -5.59M | 9.84M | 572K |
Free Cash Flow | -10.35M | -11.85M | -9.48M | -11.72M | -8.97M | -6.2M | -6.82M | -6.25M | -8.12M | -6.32M | -6.74M | -6.35M | -6.48M | -7.87M | -5.59M | -5.16M | -5.76M |